Purity CAS 274693-27-5 Ticagrelor Pharmaceutical Grade Ticagrelor API Anticoagulant Antiplatelet Ticagrelor

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: D-sung Ticagrelor
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Adult
• State: Powder
• Purity: >99%
• Product Name: Ticagrelor
• Name: Ticagrelor Powder
• Appearance: White Powder
• Color: White
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Pharmaceutical
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 274693-27-5
• Mf: C23h28f2n6o4s
• MW: 522.57
• Storage Conditions: 2-8 C
• Melting Point: 149-154 C
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• Production Capacity: 1000kg/Month

Product Description

Purity CAS 274693-27-5 Ticagrelor Pharmaceutical Grade Ticagrelor API Anticoagulant Antiplatelet Ticagrelor

Product Description

Product Details

Name	Ticagrelor
CAS	274693-27-5
Molecular Formula	C23H28F2N6O4S
Molecular weight	522.57
Apparence	White powder
Purity	99%
Advantage	OEM;ODM
Certificate	GMP/ISO9001

Ticagrelor are used to reduce the incidence of thrombotic cardiovascular events in patients with acute coronary syndroms (unstable angina, non-ST-segment elevation myocardial infarction, or ST-segment elevation myocardial infarction), including those undergoing pharmacotherapy and percutaneous coronary intervention (PCI). Compared with clopidogrel, this product reduced the incidence of cardiovascular death, myocardial infarction, or stroke combined end points

Application&Function

This product is used to reduce the incidence of thrombotic cardiovascular events in patients with acute coronary syndromes (unstable angina, non-ST-segment elevation myocardial infarction, or ST-segment elevation myocardial infarction), including those undergoing medication and percutaneous coronary intervention (PCI). Compared with clopidogrel, this product reduced the incidence of cardiovascular death, myocardial infarction, or stroke combined end points. The difference between the two treatment groups was due to cardiovascular death and myocardial infarction, but there was no difference in stroke

Specification